Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Haugh

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cancer Immunology Research|June 1, 2023
Resistance to Immune Checkpoint Blockade: IFNγ or MHC-I?Alexandra Haugh, Adil Daud
American Journal of Clinical Dermatology|February 8, 2024
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous MelanomaAlexandra Haugh, Adil I Daud
Best Practice & Research. Clinical Haematology|July 23, 2025
Cytokines and immune effector cell therapyAlexandra Haugh, Matthew J Frigault
JAMA Dermatology|April 15, 2026
Cutaneous Eruptions and Lifileucel/Interleukin 2 in Individuals With Metastatic MelanomaJordan T Said, Yunxi Li, Nakisa Sadeghi, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cancer Immunology Research|June 1, 2023
Resistance to Immune Checkpoint Blockade: IFNγ or MHC-I?Alexandra Haugh, Adil Daud
American Journal of Clinical Dermatology|February 8, 2024
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous MelanomaAlexandra Haugh, Adil I Daud
Best Practice & Research. Clinical Haematology|July 23, 2025
Cytokines and immune effector cell therapyAlexandra Haugh, Matthew J Frigault
JAMA Dermatology|April 15, 2026
Cutaneous Eruptions and Lifileucel/Interleukin 2 in Individuals With Metastatic MelanomaJordan T Said, Yunxi Li, Nakisa Sadeghi, et al.
Pageof 1